The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could provide survival benefits for locally advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR-TKI treated stage IIIB EGFRm NSCLC remains controversial. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Yicheng, Bian, Dongliang, Huang, Zhida, Yu, Huansha, Huang, Jie, Zhang, Peng, He, Wenxin, Liu, Hongcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909294/
https://www.ncbi.nlm.nih.gov/pubmed/36776292
http://dx.doi.org/10.3389/fonc.2023.1034897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909294/
https://www.ncbi.nlm.nih.gov/pubmed/36776292
http://dx.doi.org/10.3389/fonc.2023.1034897

Ejemplares similares